Latest news with #Zydus
Time of India
04-07-2025
- Health
- Time of India
Healthy outside, sick inside: The hidden danger of fatty liver
Representative Image In today's fast-paced life, it's easy to overlook what we can't feel. Fatty liver is one such condition — often silent, commonly missed, and rapidly becoming one of India's most widespread health issues. It is estimated that nearly one in three urban Indians may have fatty liver disease without being aware of it. What is fatty liver and why should you care? Fatty liver, now increasingly referred to as MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), occurs when fat accumulates excessively within liver cells. While a small amount of fat is normal, too much can impair liver function and lead to long-term complications like inflammation, fibrosis, cirrhosis, and even liver cancer. Most patients do not experience any symptoms. The condition is usually discovered during routine checkups or imaging tests done for other reasons, — making early detection even more critical. Who is at risk of fatty liver? Are you overweight? Do you have a sedentary lifestyle? Do you often consume junk food or sugar-sweetened beverages? If yes, you may be at risk. Fatty liver is no longer a disease of the elderly or those who consume alcohol. It is increasingly found in non-drinkers, young adults, and even teenagers, — largely due to poor lifestyle habits. Those with diabetes, obesity, high cholesterol, or high blood pressure are particularly vulnerable. Zydus recently launched #LiverKiSuno, a public awareness initiative aimed at promoting healthy lifestyle habits for better liver health. Such campaigns play a vital role in increasing awareness about liver-related conditions and educating the public on effective prevention and management strategies. How does fatty liver progress over time? Can a little fat in the liver really harm you? The answer is yes. If not addressed early, fatty liver can silently progress over the years from a mild stage to serious liver damage. This damage may not be reversible in advanced stages and can ultimately lead to liver failure or cancer. That's why early diagnosis and lifestyle modification are the best ways to protect your liver. What can you do to reverse fatty liver? Is fatty liver treatable? Absolutely — especially in its early stages, and the first step is not a pill, but a lifestyle change. Exercise is key. Brisk walking, cycling, or swimming for at least 30–45 minutes most days of the week can significantly reduce liver fat. Gradual weight loss is effective — even losing 5 to 10 percent of body weight can make a measurable difference. Equally important is diet. Avoid junk food and ultra-processed items like chips, biscuits, and sugary drinks. Cut down on refined carbs like white bread and fried foods. Choose whole grains, fruits, vegetables, and home-cooked meals rich in fibere and low in saturated fats. Sleep also plays a vital role. Studies show that sleeping less than 6 hours regularly can worsen insulin resistance and liver health. Aim for a good 7 hours of quality sleep every night. Should you get tested? If you're at risk — even without symptoms — it's wise to get screened. A simple ultrasound and basic liver function tests can help detect fatty liver early. The Liver Never Complains — Until It's Too Late. Your liver quietly performs over 500 essential functions every day. It digests food, stores energy, filters toxins, and keeps you alive — all without making a sound. Don't wait for a problem to show up. Start today. Eat clean. Move more. Sleep well. And take charge of your liver health before it's too late. Author: Dr Rajiv Mehta Consultant Liver Specialist SIDS Hospital and Research Centre Surat The above is non-editorial content and TIL does not guarantee, vouch or endorse any of it. Please take all steps necessary to ascertain that any information and content provided is correct, updated, and verified.
Economic Times
23-06-2025
- Business
- Economic Times
Go on, pop the innovation pill: ₹5,000 cr push signals India's shift from copy to create
Stir things up Rollout of the ₹5,000-cr Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme signals a shift in how India approaches the sector's growth. This initiative, expected to begin disbursals by the end of 2025, could attract ₹17,000 cr in additional R&D investment. For an industry that has long been associated with generic manufacturing, this represents a paradigm shift towards innovation-led pharma world is approaching a 'patent cliff', and for Indian firms, it represents an unprecedented opportunity: 24 mega-selling drugs with combined annual sales exceeding $250 bn will lose patent protection by 2030. This means blockbuster medicines like Humira for rheumatoid arthritis, Keytruda for cancer treatment, Stelara for psoriasis, and Symbicort for asthma will soon be open for generic manufacturing. When these patents expire, drug prices fall by at least 50%. For a country where out-of-pocket (OoP) healthcare expenses are high, this holds immense significance alongside its commercial potential. Capturing these opportunities won't be easy. Indian firms will face tough competition from generics and must match the original drug standards. Success will hinge on investment in bioequivalence studies, regulatory compliance and resilient supply chains. Indian pharma companies are eyeing these opportunities. Zydus, Sun Pharma, and Bharat Serums and Vaccines (now part of Mankind Pharma) have invested in establishing world-class R&D centres, focusing on developing new chemical entities. The younger generation of scientists and entrepreneurs, bringing fresh perspectives, is accelerating the transition from a generic-focused industry to one that balances both generic excellence and innovative drug discovery. MNCs are also rethinking their view of the Indian market: Novartis, Novo Nordisk and Eli Lilly have chosen to out-license their brands to Indian firms rather than directly market them here. This trend reflects both the growing capabilities of domestic firms and the unique challenges of serving India's diverse and price-sensitive market. These partnerships benefit all. International companies can maintain a presence in India without the complexities of direct operations, while Indian firms gain access to established brands and molecules, leveraging deep market understanding and extensive distribution networks. However, building these relationships requires investment in compliance systems, quality infrastructure, and continuous capability upgrades to meet the exacting standards of international positives in the sector include: Exemption of 36 life-saving drugs from basic customs duty will benefit companies bringing in innovative medicines. Drugs like AstraZeneca's Selumetinib, Pfizer's Lorlatinib, Novartis' Ribociclib, and GSK's Mepolizumab will now be more affordable. Additionally, six more life-saving medicines have been added to the concessional 5% duty slab, primarily targeting cancer, rare diseases and other chronic conditions. The health budget has risen to over ₹95,000 cr for FY26, up 9.46%. More than a numbers game, it's about building a healthcare ecosystem fit for our vast population. 15,479 Jan Aushadhi Kendras provide generic medicines at prices up to 80% lower than branded equivalents. A heart medicine that once cost ₹500 is available for ₹100, bringing essential treatments within reach of ordinary citizens. Yet, ensuring consistent quality and maintaining reliable supply chains remain a challenge. Extension of PM Ayushman Yojana to people above 70 years creates a virtuous cycle - more people seeking treatment drives demand for medicines, which, in turn, encourages pharma companies to invest in better products and wider distribution. Development of healthcare infra in tier-2 and tier-3 cities is also helping. However, attracting and retaining qualified medical professionals in these locations remains a hurdle, requiring innovative approaches to compensation, career development and quality-of-life considerations. Again, the market for pharma products will, then, be able to expand. A 'nutraceutical revolution' is underway. With the market expected to grow from $4 bn in 2020 to $18 bn by December, nutraceuticals represent a significant growth avenue for companies willing to invest in quality and innovation. The convergence of multiple factors - patent opportunities, GoI support, infrastructure development and changing consumer behaviour - is creating unprecedented opportunities for the sector. Companies that embrace innovation, while maintaining traditional strengths in affordable healthcare delivery, will thrive. The writer is CEO, Mankind Pharma (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Second only to L&T, but controversies may weaken this infra powerhouse's growth story Looking for quick buck in unlisted shares? Better think twice! How Vedanta's Anil Agarwal bettered Warren Buffett in returns Rivers are moving more goods than before. But why aren't they making a splash yet? Stock Radar: Supreme Industries stock down by about 30%! Breakout from rounding bottom formation suggests bulls are catching up Two Trades for Today: A large-cap auto major for 6.7% gain, a mid-cap auto stock for almost 7% rise After a gap of 4 years, are HDFC, Axis, Kotak banks ready for re-rating? 5 bank stocks with upside potential of up to 35% For medium- to long-term investors with moderate risk appetite: 6 large-cap stocks with an upside potential of up to 40%
The Hindu
18-06-2025
- Business
- The Hindu
U.S. FDA issues two observations to Zydus' oncology injectable plant in Ahmedabad
U.S. Food and Drug Administration (FDA) has issued two observations to the oncology injectable plant of Zydus in Ahmedabad. The observations were issued following a GMP follow-up inspection of the facility in SEZ 1, near Matoda from June 9-18. They were not related to data integrity. The company will closely work with the U.S. FDA to address and respond to the observations in an expeditious manner, Zydus said on Wednesday.
Business Upturn
18-06-2025
- Business
- Business Upturn
Zydus completes USFDA inspection at oncology plant with two minor observations, none related to data integrity
By Aditya Bhagchandani Published on June 18, 2025, 16:48 IST Zydus Lifesciences Ltd has announced the successful conclusion of a Good Manufacturing Practices (GMP) follow-up inspection by the United States Food and Drug Administration (USFDA) at its oncology injectable manufacturing facility located at SEZ 1, near Matoda, Ahmedabad. The inspection was conducted over a 10-day period, from June 9 to June 18, 2025. In a regulatory filing to the stock exchanges, the company stated, 'We wish to inform that the US Food and Drug Administration (USFDA) conducted a GMP follow-up inspection at the company's oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad.' The company further added that the inspection concluded with two observations, emphasizing that 'none of them were related to data integrity.' Zydus assured stakeholders that it is taking these observations seriously and is committed to addressing them promptly. 'The Company will closely work with the USFDA to address and respond to the observations in an expeditious manner,' the statement read. This update has been provided in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Zydus also requested that this development be 'brought to the notice of the members of the exchange and the investors at large.' The successful closure of the inspection without any data integrity issues is a positive sign for Zydus, reaffirming its compliance with global manufacturing standards in a critical therapeutic segment. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
17-06-2025
- Business
- Business Upturn
Pharma stocks in focus as Trump announces tariffs on sector ‘soon'
Indian pharmaceutical stocks are in focus today after U.S. President Donald Trump announced that pharma tariffs are coming very soon. According to industry data, companies with the highest U.S. revenue exposure include Alembic Pharma (50%+), Aurobindo Pharma (45%+), and Dr. Reddy's and Zydus (both 40%). These firms are likely to be the most impacted if tariffs are introduced or raised on pharmaceutical imports from India. Here's a quick look at U.S. revenue exposure for key Indian pharma companies: Company % Revenue from U.S. Alembic 50%+ Aurobindo 45%+ Dr. Reddy's 40% Zydus 40% Lupin 34–38% Sun Pharma 30–35% Glenmark 30% Cipla 25–30% Torrent ~15–20% Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
